
Nextcea
Woburn, MA, United States nextcea.com From their website, Nov 2026
- GLP
Work here? Claim this listing
About
Nextcea provides biomarker and drug target engagement services for drug efficacy and safety assessment in nonclinical and clinical studies. It works on neurodegenerative diseases and cancer drug development from Woburn, Massachusetts.
Services
Biomarker and drug target engagement services
Provides biomarker and target engagement support for drug efficacy and safety assessment across development stages.
LC-MS/MS biomarker quantitation
Integrates LC-MS/MS biomarker quantitation for efficacy and safety studies.
PK/PD assessment
Supports pharmacokinetic/pharmacodynamic efficacy assessments.
TK/TD safety evaluation
Supports toxicokinetic/toxicodynamic safety evaluations.
Phospholipidosis / Parkinsonism assessment
Offers services focused on drug-induced phospholipidosis and Parkinsonism.
LRRK2 Parkinson’s assessment
Provides biomarker services related to LRRK2 in Parkinson’s disease.
GBA Parkinson’s and Gaucher disease assessment
Provides biomarker services related to GBA in Parkinson’s disease and Gaucher disease.
Kidney safety assessment
Provides kidney safety assessment for oligonucleotide drug candidates.
1 more services
- BTK leukemia / lymphoma assessment
Capabilities
- Assays and studies
- LC-MS/MS
- PK/PD
- Oligonucleotides
- Biomarker quantitation
- Drug target engagement
- TK/TD
4 more
- Clinical trials
- Non-clinical studies
- GLP validated bioanalytical methods
- Electronic records
- Therapeutic areas
- Neurodegenerative diseases
- Parkinson’s disease
- Gaucher disease
- Dementia
- Leukemia
- Lymphoma
- Kidney safety
Instruments and platforms
- UPLC-MS/MS 7500
Modalities and species
- Modalities
- Oligonucleotide
Certifications
As the company states them, with the certificate or registry record where there is one.
GLPSelf-reported
Scope: non-clinical and clinical studies
Details
- Founded
- 2006
- Address
- 500 West Cummings Park Suite #4550 Woburn, MA 01801
- Serves
- Globally